Pipeline | S-Quatre Corporation

エディタV2

Cerebral palsy

Cerebral palsy is a permanent impairment of posture and motor function due to a perinatal brain damage, that can lead to intellectual disability. The most common causes include hypoxia during the perinatal period, maternal infection during the fetal period, and low birth weight due to premature birth.
Despite advances in perinatal care, the incidence of cerebral palsy has not decreased. It is estimated to occur in about 1 in 500 newborns, or 78,000 patients in Japan, of whom 24,000 are under the age of 18, or 240,000 patients under the age of 10 in total of Japan, the US, and the EU.

Neonatal phase (acute stage)

Because of the limited efficacy of hypothermia therapy for preventing cerebral palsy in neonates with suspected hypoxic-ischemic encephalopathy (HIE), the administration of autologous cord blood stem cells has been studied.

Pediatric phase (chronic stage)

New therapies are desired due to the lack of established treatment, although various types of rehabilitation are being implemented. Botulinum toxin is sometimes used to treat spasticity.
Cerebral palsy often becomes apparent as the child grows, even if no abnormalities are detected at birth.

GCT-103

In the animal models of pediatric cerebral palsy (PCP), intravenous administration of SQ-SHED has been confirmed to improve motor deficits by enhancing nerve growth or neurogenesis in the brain in our own study or the collaboration study with Nagoya University, promising a potential new therapy for PCP.
A clinical study to see the tolerability and efficacy of autologous SQ-SHED is ongoing at Nagoya University. We also plan to initiate a clinical trial of allogeneic SQ-SHED manufactured from the S-Quatre^® master cell bank.

Publication

Spinal Cord Injury

Protective Mechanism of Stem Cells from Human Exfoliated Deciduous Teeth in Treating Spinal Cord Injury. J Neurotrauma
Nishii T, Osuka K, Nishimura Y, Ohmichi Y, Ohmichi M, Suzuki C, Nagashima Y, Oyama T, Abe T, Kato H, Saito R.
J Neurotrauma. 2024 Jan 23. doi: 10.1089/neu.2023.0251. Epub ahead of print. PMID: 38185837.

Brain Cancer

Efficacy of HSV-TK/GCV system suicide gene therapy using SHED expressing modified HSV-TK against lung cancer brain metastases
Oishi T, Ito M, Koizumi S, Horikawa M, Yamamoto T, Yamagishi S, Yamasaki T, Sameshima T, Suzuki T, Sugimura H, Namba H, Kurozumi K.
Mol Ther Methods Clin Dev. 2022 Jul 6;26:253-265. doi: 10.1016/j.omtm.2022.07.001. PMID: 35892087. PMCID: PMC9307584.

Potent bystander effect and tumor tropism in suicide gene therapy using stem cells from human exfoliated deciduous teeth
Horikawa M, Koizumi S, Oishi T, Yamamoto T, Ikeno M, Ito M, Yamasaki T, Amano S, Sameshima T, Mitani Y, Otani Y, Yan Y, Suzuki T, Namba H, Kurozumi K.
Cancer Gene Ther. 2023 Jan;30(1):85-95. doi: 10.1038/s41417-022-00527-5. Epub 2022 Sep 8. PMID: 36076062.

Migration Capacity of Stem Cells from Human Exfoliated Deciduous Teeth Towards Glioma
Yamamoto T, Koizumi S, Oishi T, Horikawa M, Asakawa T, Yamasaki T, Sameshima T, Mitani Y, Namba H, Kurozumi K.
J Integr Neurosci. 2022 Nov 25;22(1):1. doi: 10.31083/j.jin2201001. PMID: 36722233.